Diagnostics

The 48-year-old actor launched Colin Farrell Foundation initiating and promoting progressive programs for people who are struggling with this intellectual disability

This agreement follows previous disclosures by Aurobindo Pharma about expanding its biologics manufacturing facilities and exploring contract manufacturing operations (CMO) for biologicals

Company said to be considering acquiring majority stake in dedicated diagnostic services firm

In past one year, the market price of Vijaya has been more than doubled or zoomed 116%, as against 17% rise in the S&P BSE Sensex.

.

The participation aims to add to the diagnostic service provider's international portfolio. Its international network consists of several centres and pick-up points (PUPs) across multiple locations

The company employs diagnostic laboratory (lab) principles through a smartphone application (app) and a test card

It is unclear whether the finalisation of the NEDL will lead to price capping of diagnostic tests in line with drugs

.

Tencent-backed healthcare and diagnostics app Practo is aiming to turn profitable in next fiscal and is looking at a stock exchange listing with an initial public offering (IPO) soon, its co-founder and CEO Shashank ND said. Practo is looking to enhance presence in smaller cities and towns and leverage AI to analyse data and provide much better analysis and outcomes in healthcare. In an interview with PTI, Shashank said the startup is already cash flow positive. "This year we will grow by a good healthy margin... Our EBITDA would have improved dramatically from last year. We will be near break-even this year and next year is when we really will be able to show significant profits." Founded in 2008, Practo connects doctors with patients and offers several ancillary services such as telemedicine. Income from diagnostic and consulting services formed 50 per cent of the total operating revenue. In the 2022-23 fiscal (April 2022 to March 2023), the Bengaluru-headquartered firm halved it

The groundbreaking research into attosecond pulses opens doors to a new era of scientific exploration with applications spanning physics, chemistry, engineering and medical diagnostics

Neuberg Diagnostics Pvt Ltd has completed the merger of Neuberg Supratech Reference Laboratory, Ahmedabad, and Neuberg Anand Reference Laboratory, Bengaluru, thereby setting the ball rolling for its IPO plans, the company said on Wednesday. With a strategic vision to streamline operations and enhance efficiency, the merger brings together two entities under Neuberg Diagnostics Pvt Ltd. The merger also paves the way for Neuberg Diagnostics' launch of its Initial Public Offering (IPO) by 2024 or 2025, a company statement here said. "This merger marks a significant step forward in our journey to provide unparalleled healthcare solutions. By integrating these renowned laboratories, we reinforce our commitment to delivering excellence in diagnostics and patient care," said Neuberg Diagnostics Chairman and Managing Director GSK Velu. As a result of the acquisition, the group gross revenue of Neuberg Diagnostics is expected to be over Rs 1,000 crore during the current financial year. The

Collaborative and collective efforts among countries in the WHO South-East Asia Region and equitable access to prevention, diagnosis and treatment options are pivotal to ending TB, Union Health Minister Mansukh Mandaviya said on Thursday, citing the lessons from the COVID-19 pandemic. Delivering the keynote address at a ministerial meeting on "Sustain, Accelerate, and Innovate to end TB in the South-East Asia Region", Mandaviya reiterated India's commitment of eliminating TB from the country by 2025, five years ahead of the global deadline. The meeting was co-chaired by WHO Director-General Tedros Adhanom Ghebreyesus here on Thursday. The event witnessed a significant milestone in the signing of the Gandhinagar Declaration, which calls for establishing a high-level multisectoral commission reporting to the highest political level in each country for synergy of efforts among various stakeholders and to monitor progress towards ending TB and other priority diseases. The declaration i

Diagnostics platform Redcliffe Labs is looking to scale up its operations with 250 laboratories and 10,000 collection centres by 2025 and plans to go public in 2025-26, according to its founder and Managing Director Dheeraj Jain. The company, which commenced operations in 2018, has 81 laboratories and over 2,000 collection centres in small cities and towns. Redcliffe Labs, which has raised USD 80 million so far, has set an ambitious target of having 700 laboratories and 25,000 collection centres by 2027-28. In an interaction with PTI, Jain said the short-term target is to have 10,000 collection centres and 250 laboratories by 2025. He noted that the majority of the expansion will be in Tier II, Tier III and Tier IV locations across states like Uttar Pradesh, Madhya Pradesh, Rajasthan, Bihar, Jharkhand and Chattisgarh which have less developed infrastructure for diagnostics. "We are also looking at simplifying the reports with AI technology, going deeper in states where we are pres

'The Mylab ecosystem is capable of providing solutions'

While discounts have come down, pricing gap still large between incumbents and new players

While discounts have come down, pricing gap still large between incumbents and new players

Online players had kept rates low, but with Covid time volumes gone, the trend is changing

Thyrocare is diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that centre on early detection and management of health disorders and diseases.

Fertility treatments chain Indira IVF on Tuesday announced a foray into the diagnostics sector with a Rs 60 crore investment over the next five years. The city-based company, which claims to India's largest fertility treatments chain, plans to offer pathology tests catering to the needs of women and children, as per an official statement. It plans to have over 30 laboratories by FY24, which will include centres in Lucknow, Patna, New Delhi, Mumbai, Pune, Udaipur, Jaipur, Varanasi, Kolkata, Ranchi, Bhubaneswar and Bengaluru, it said. The TA Associates-backed chain plans to invest Rs 50-60 crore for Indira Pathlabs over next five years which may even exceed depending on future plans and opportunities, the statement said.